NorthStar Medical Radioisotopes and Point Biopharma Global have signed a supply agreement covering the development and commercialization of the medical radioisotope actinium-225 (Ac-225).
Under the deal, NorthStar will provide its electron accelerator-produced Ac-225 to Point. Point will use the radioisotope in the investigational studies of PNT2001, a prostate-specific membrane antigen (PSMA) for nonmetastatic castrate-sensitive prostate cancer and PNT2004, a fibroblast activation protein-α candidate with potential pan-cancer applications.
Also, Ac-225 will be used to advance Point's new tumor microenvironment tumor-targeting platform.
